Dr. Lei Mao Takes Leadership as Chair of IPAC-RS for New Term

Transpire Bio Inc., a pioneering clinical-stage biopharmaceutical company based in the U.S., has recently announced that Dr. Lei Mao, the company's Head of External Research, has been elected to chair the International Pharmaceutical Aerosol Consortium on Regulation Science (IPAC-RS) for the upcoming term spanning 2026 to 2028. This prestigious appointment marks a significant milestone not only in Dr. Mao's career but also for Transpire Bio, reflecting the company's commitment to making substantial advancements in inhalation therapies.

The IPAC-RS is a notable non-profit organization that comprises industry leaders involved in the development, manufacture, marketing, and research support of inhaled and nasal drugs and biologics. The consortium plays a vital role in advocating for regulatory changes that benefit the inhalation industry while fostering scientific progress in areas of collective interest. Dr. Mao succeeds Jennifer Wylie as Chair, stepping into a role that is crucial during a time of rapid evolution in both scientific and regulatory landscapes.

Dr. Xian-Ming Zeng, CEO of Transpire Bio, expressed pride in Dr. Mao's election. He stated, “His election reflects both his individual and scientific expertise and highlights Transpire Bio's position as a global thought leader in inhalation and inhaled drug-device combination products.” This leadership position reinforces the company's dedication to partnering with organizations like IPAC-RS, which is critical for shaping the regulatory landscape that supports innovative inhalation therapies.

“I am honored to assume the role of Board Chair for IPAC-RS during this period of significant scientific and regulatory evolution,” Dr. Mao commented. He emphasized the importance of collaboration with international partners, academic institutions, and regulatory bodies to streamline the pathways needed for delivering high-quality inhaled medicines. His vision encompasses enhancing global access to crucial therapies that could greatly improve patient outcomes.

Founded in Sunrise, Florida, Transpire Bio is dedicated to developing inhaled therapeutics aimed at treating various pulmonary and systemic diseases. The company has harnessed its expertise in inhaled drug delivery to address unmet medical needs and improve the lives of patients with conditions where treatment options are severely limited. Among its innovations are proprietary technologies including dry powder inhalers and soft mist inhalers, which are essential in making treatments more accessible.

Currently, Transpire Bio is working on a pipeline of inhaled therapies designed to combat diseases such as Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial Hypertension (PAH), Diabetes, and Obesity. The strategic direction set under Dr. Mao's leadership is expected to accelerate the company's mission to provide transformative therapies to patients worldwide.

As Dr. Mao embarks on this new role, the industry watches closely, hopeful that his leadership will steer important discussions and regulatory changes that could reshape how inhaled therapies are developed and accessed. The next two years promise to be a dynamic and impactful chapter for the IPAC-RS as it navigates the challenges and opportunities that lie ahead in the global healthcare landscape.

In conclusion, Dr. Lei Mao's appointment as Chair of the IPAC-RS is not only a testament to his leadership but also a significant development in the field of inhaled therapeutics. With a concerted effort to collaborate and innovate, the future looks bright for patients and the industry alike as we look toward advancements that will improve treatment options on a global scale.